Efficacy comparation of different neoadjuvant chemotherapies combined with trastu-zumab and pertuzumab in HER-2 positive breast cancer
10.12354/j.issn.1000-8179.2023.20231078
- VernacularTitle:新辅助化疗联合双靶治疗HER-2阳性乳腺癌的有效性比较
- Author:
Jie MIN
1
;
Xinxin LI
;
Xin WANG
Author Information
1. 天津医科大学肿瘤医院乳腺一科,国家恶性肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,乳腺癌防治教育部重点实验室,天津市"肿瘤防治"重点实验室(天津市 300060)
- Keywords:
breast cancer;
HER-2 positive;
neoadjuvant therapy;
targeted therapy;
efficacy
- From:
Chinese Journal of Clinical Oncology
2023;50(22):1142-1146
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy of taxane + carboplatin combined with trastuzumab and pertuzumab(TCbHP),taxane com-bined with trastuzumab and pertuzumab(THP)and anthracycline + cyclophosphamide followed by taxane + trastuzumab + pertuzumab(AC-THP)as neoadjuvant therapy strategies for breast cancer patients with human epidermal growth factor receptor-2(HER-2)positive hor-mone receptor(HR)positive and HER-2 positive HR negative cancers,respectively.Methods:We retrospectively analyzed clinicopathological data of 408 HER-2 positive breast cancer patients receiving standard neoadjuvant therapy from Tianjin Medical University Cancer Institute&Hospital from June 2019 to December 2022.Stratified by HR,211 of 408 were HER-2 positive HR positive,and 197 of 408 were HER-2 posit-ive HR negative.Participants were further assigned into a TCbHP group,a THP group,and an AC-THP group according to their differing neo-adjuvant regimens,and their pathologic complete response(pCR)rates were compared.Results:Among the HER-2 positive HR positive pa-tients,the respective pCR rates of the TCbHP,THP,and AC-THP groups were 43.1%(69/160),36.0%(9/25),and 38.5%(10/26)with no stat-istical significance(χ2=0.580,P=0.748).Among the HER-2 positive HR negative patients,the respective pCR rates of the TCbHP,THP,and AC-THP groups were 85.5%(94/110),57.3%(43/75),and 66.7%(8/12)with a statistically significant difference between the TCbHP and THP groups(χ2=19.967,P<0.001).Conclusions:TCbHP,THP,and AC-THP as neoadjuvant regimens exerted similar efficacy in treating HER-2 posit-ive HR positive breast cancer.TCbHP exhibited superior efficacy in HER-2 positive HR negative breast cancer.
